FY2016 EPS Estimates for Dicerna Pharmaceuticals Inc. Increased by Leerink Swann (DRNA)
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) – Equities researchers at Leerink Swann raised their FY2016 earnings per share estimates for Dicerna Pharmaceuticals in a report issued on Monday. Leerink Swann analyst M. Schmidt now anticipates that the brokerage will post earnings of ($2.89) per share for the year, up from their prior estimate of ($3.54). Leerink Swann currently has a “Buy” rating and a $8.00 target price on the stock. Leerink Swann also issued estimates for Dicerna Pharmaceuticals’ Q4 2016 earnings at ($0.69) EPS and FY2017 earnings at ($2.82) EPS.
DRNA has been the topic of a number of other reports. Zacks Investment Research lowered Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 5th. Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Friday, August 5th. Stifel Nicolaus reissued a “buy” rating and set a $13.00 target price on shares of Dicerna Pharmaceuticals in a research report on Wednesday, September 28th. Finally, Chardan Capital decreased their target price on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating on the stock in a research report on Monday, August 15th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $9.85.
Dicerna Pharmaceuticals (NASDAQ:DRNA) opened at 3.48 on Thursday. Dicerna Pharmaceuticals has a one year low of $2.69 and a one year high of $15.93. The stock’s market cap is $72.22 million. The firm’s 50-day moving average is $4.11 and its 200 day moving average is $3.67.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.17. The firm had revenue of $162 million for the quarter.
Large investors have recently added to or reduced their stakes in the stock. Oxford Asset Management increased its stake in Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 149,560 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Dicerna Pharmaceuticals during the first quarter worth $343,000. Paloma Partners Management Co bought a new stake in Dicerna Pharmaceuticals during the second quarter worth $183,000. A.R.T. Advisors LLC bought a new stake in Dicerna Pharmaceuticals during the second quarter worth $170,000. Finally, FMR LLC increased its stake in Dicerna Pharmaceuticals by 0.4% in the second quarter. FMR LLC now owns 3,108,916 shares of the biopharmaceutical company’s stock worth $9,327,000 after buying an additional 11,719 shares during the last quarter. 62.37% of the stock is currently owned by institutional investors.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.